Online inquiry

IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14556MR)

This product GTTS-WQ14556MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), B cell acute lymphoblastic leukemia (B cell ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14556MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5358MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ4318MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIVV009
GTTS-WQ8338MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ15940MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ6100MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ12837MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ9747MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ2855MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-570
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW